Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide further ...
This summer is likely to be an emotional time for many in Ulverston.
EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy: Basel Monday, March 3, 2025, 10:00 Hrs [IST] Novartis announc ...
An Australian biotech minnow wants to become the first company globally to register an over-the-counter cannabidiol product ...
Additionally, preliminary results from Stage 3 of the OUtMATCH study provide early data on introducing allergenic foods into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results